Clinical data | |
---|---|
Trade names | Tranxene, Tranxilium, Novo-Clopate |
Other names | Clorazepate dipotassium |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682052 |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 91% |
Metabolism | Hepatic |
Elimination half-life | 48 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.041.737 |
Chemical and physical data | |
Formula | C16H11ClN2O3 |
Molar mass | 314.73 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Clorazepate, sold under the brand name Tranxene among others, is a benzodiazepine medication. It possesses anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxant properties. Clorazepate is an unusually long-lasting benzodiazepine and serves as a prodrug for the equally long-lasting desmethyldiazepam, which is rapidly produced as an active metabolite. Desmethyldiazepam is responsible for most of the therapeutic effects of clorazepate.[2]
It was patented in 1965 and approved for medical use in 1967.[3]